BR112021024117A2 - Pirazolo-pirazinas substituídas e seu uso como moduladores do receptor de glun2b - Google Patents
Pirazolo-pirazinas substituídas e seu uso como moduladores do receptor de glun2bInfo
- Publication number
- BR112021024117A2 BR112021024117A2 BR112021024117A BR112021024117A BR112021024117A2 BR 112021024117 A2 BR112021024117 A2 BR 112021024117A2 BR 112021024117 A BR112021024117 A BR 112021024117A BR 112021024117 A BR112021024117 A BR 112021024117A BR 112021024117 A2 BR112021024117 A2 BR 112021024117A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyrazines
- glun2b receptor
- receptor modulators
- glun2b
- substituted pyrazol
- Prior art date
Links
- 108010054200 NR2B NMDA receptor Proteins 0.000 title abstract 5
- NPPLQHRDPZHEEW-UHFFFAOYSA-N pyrazine;1h-pyrazole Chemical class C=1C=NNC=1.C1=CN=CC=N1 NPPLQHRDPZHEEW-UHFFFAOYSA-N 0.000 title 1
- DDZGQYREBDXECY-UHFFFAOYSA-N 1h-pyrazolo[3,4-b]pyrazine Chemical class C1=CN=C2C=NNC2=N1 DDZGQYREBDXECY-UHFFFAOYSA-N 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861681P | 2019-06-14 | 2019-06-14 | |
| PCT/EP2020/066405 WO2020249802A1 (en) | 2019-06-14 | 2020-06-12 | Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021024117A2 true BR112021024117A2 (pt) | 2022-03-22 |
Family
ID=71111400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021024117A BR112021024117A2 (pt) | 2019-06-14 | 2020-06-12 | Pirazolo-pirazinas substituídas e seu uso como moduladores do receptor de glun2b |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11214563B2 (https=) |
| EP (1) | EP3983413A1 (https=) |
| JP (1) | JP2022536773A (https=) |
| KR (1) | KR20220024403A (https=) |
| CN (1) | CN114008052A (https=) |
| AU (1) | AU2020292994A1 (https=) |
| BR (1) | BR112021024117A2 (https=) |
| CA (1) | CA3143105A1 (https=) |
| MX (1) | MX2021015500A (https=) |
| WO (1) | WO2020249802A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| MX2021015511A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Carbamatos de pirazina y sus usos como moduladores del receptor glun2b. |
| CA3143103A1 (en) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Pyridine carbamates and their use as glun2b receptor modulators |
| AU2020293642A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators |
| TW202112774A (zh) | 2019-06-14 | 2021-04-01 | 比利時商健生藥品公司 | 經取代之吡唑并－吡啶醯胺及其作為ｇｌｕｎ２ｂ受體調節劑之用途 |
| JP7667097B2 (ja) | 2019-06-14 | 2025-04-22 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用 |
| BR112021025141A2 (pt) | 2019-06-14 | 2022-01-25 | Janssen Pharmaceutica Nv | Pirazolo-piridinas heteroaromáticas substituídas e seu uso como moduladores do receptor glun2b |
| CN114008052A (zh) | 2019-06-14 | 2022-02-01 | 詹森药业有限公司 | 取代的吡唑并-吡嗪以及它们作为GluN2B受体调节剂的用途 |
| EP4669318A1 (en) * | 2023-02-23 | 2025-12-31 | The Rockefeller University | 1-ACYL-3-AMINOINDAZOLES FOR THE TREATMENT OF CYSTIC FIBROSIS |
| KR20250094560A (ko) | 2023-12-15 | 2025-06-25 | 서울대학교산학협력단 | GluN2B 억제제를 유효성분으로 포함하는 페닐케톤뇨증 및 고페닐알라닌혈증의 뇌기능 장애 예방, 개선 또는 치료용 조성물 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT97888B (pt) | 1990-06-07 | 1998-12-31 | Zeneca Ltd | Processo para a preparacao de compostos heterociclicos derivados de indol e de composicoes farmaceuticas que os contem |
| GB9407447D0 (en) | 1994-04-14 | 1994-06-08 | Glaxo Group Ltd | Chemical compounds |
| DE69730980T2 (de) | 1996-07-31 | 2006-02-23 | Nikken Chemicals Co., Ltd. | 6-phenyltetrahydro-1,3-oxazin-2-on derivate und medizinische zusammensetzungen, die sie enthalten |
| EP1296958A4 (en) | 2000-06-26 | 2004-01-28 | Merck & Co Inc | ANTIAGONISTS OF NMDA NR2B RECEPTORS OF IMINOPYRIMIDINE |
| US6610723B2 (en) | 2001-01-29 | 2003-08-26 | Hoffmann-La Roche Inc. | Imidazole derivatives |
| DE60316542T2 (de) | 2002-03-28 | 2008-07-03 | Eisai R&D Management Co., Ltd. | 7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen |
| US7005432B2 (en) | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| US7429609B2 (en) | 2002-05-31 | 2008-09-30 | Eisai R & D Management Co., Ltd. | Pyrazole compound and medicinal composition containing the same |
| CA2537916A1 (en) | 2003-09-03 | 2005-03-31 | Neurogen Corporation | 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds |
| RU2006127575A (ru) | 2004-02-18 | 2008-03-27 | Астразенека Аб (Se) | Соединение триазола и их применение в качестве антагонистов метаботропного рецептора глутамата |
| CA2581454A1 (en) | 2004-09-23 | 2006-03-30 | Reddy Us Therapeutics, Inc. | Novel pyrimidine compounds, process for their preparation and compositions containing them |
| WO2006058120A1 (en) | 2004-11-22 | 2006-06-01 | Vertex Pharmaceuticals Incorporated | Bicyclic inhibitors or rho kinase |
| WO2007115231A2 (en) | 2006-03-30 | 2007-10-11 | Chemocentryx, Inc. | Cxcr4 modulators |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| EP2167464B1 (en) | 2007-05-25 | 2014-12-03 | AbbVie Deutschland GmbH & Co KG | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor) |
| WO2009004430A1 (en) | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors |
| JPWO2009028543A1 (ja) | 2007-08-30 | 2010-12-02 | 武田薬品工業株式会社 | 置換ピラゾール誘導体 |
| EP2215073A4 (en) | 2007-10-31 | 2011-04-06 | Merck Sharp & Dohme | SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS |
| MX2010009649A (es) | 2008-03-27 | 2010-12-17 | Evotecv Neurosciences Gmbh | Metodos para tratar trastornos utilizando un antagonista selectivo del subtipo nr2b de nmda. |
| JPWO2009157196A1 (ja) | 2008-06-25 | 2011-12-08 | 武田薬品工業株式会社 | アミド化合物 |
| BRPI0917540A2 (pt) | 2008-08-05 | 2015-11-17 | Daiichi Sankyo Co Ltd | composto, sal farmacologicamente aceitavél, composição farmacêutica, e, uso de um composto ou sal farmacologicamente aceitável |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| WO2010043396A1 (en) | 2008-10-16 | 2010-04-22 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
| KR101048448B1 (ko) | 2008-11-21 | 2011-07-11 | 한국화학연구원 | 신규 피라졸로[4,3-ｂ]피리딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물 |
| WO2010068483A2 (en) | 2008-11-25 | 2010-06-17 | University Of Rochester | Mlk inhibitors and methods of use |
| US8969342B2 (en) | 2009-03-20 | 2015-03-03 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
| US8906914B2 (en) | 2009-08-18 | 2014-12-09 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid hydrolase |
| EP2579717A4 (en) | 2010-06-09 | 2013-12-11 | Merck Sharp & Dohme | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 |
| DK2669270T3 (en) | 2011-01-28 | 2018-02-26 | Sato Pharma | Indole-related compounds such as URAT1 inhibitors |
| JP2012188363A (ja) | 2011-03-09 | 2012-10-04 | Dainippon Sumitomo Pharma Co Ltd | アザベンゾイミダゾロン誘導体 |
| MX2014001088A (es) | 2011-07-28 | 2015-03-19 | Chdi Foundation Inc | Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas. |
| PT2570415E (pt) * | 2011-09-19 | 2015-11-23 | Sanofi Sa | N-[4-(1h-pirazolo[3,4-b]pirazin-6-il)-fenil]-sulfonamidas e a sua utilização como fármacos |
| WO2013060029A1 (en) | 2011-10-28 | 2013-05-02 | Merck Sharp & Dohme Corp | Allosteric modulators of metabotropic glutamate receptors |
| WO2013130855A1 (en) | 2012-03-02 | 2013-09-06 | Takeda Pharmaceutical Company Limited | Indazole derivatives |
| MA37975B2 (fr) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| JP2016506962A (ja) | 2013-01-29 | 2016-03-07 | ノーレックス, インコーポレイテッドNaurex, Inc. | スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用 |
| WO2014124651A1 (en) | 2013-02-15 | 2014-08-21 | Københavns Universitet | Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists |
| EP2970200A1 (en) | 2013-03-13 | 2016-01-20 | Abbvie Inc. | Pyridine cdk9 kinase inhibitors |
| DK2970265T3 (en) | 2013-03-15 | 2018-10-01 | Plexxikon Inc | HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF |
| SI3010503T1 (sl) | 2013-06-21 | 2020-07-31 | Zenith Epigenetics Ltd. | Novi biciklični inhibitorji bromodomene |
| RS58361B1 (sr) | 2013-07-31 | 2019-03-29 | Merck Patent Gmbh | Piridini, pirimidini i pirazini, kao inhibitori btk i njihova upotreba |
| US10155727B2 (en) | 2014-08-15 | 2018-12-18 | Janssen Pharmaceuticals, Inc. | Pyrazoles |
| WO2016025917A1 (en) | 2014-08-15 | 2016-02-18 | Janssen Pharmaceuticals, Inc. | Triazoles as nr2b receptor inhibitors |
| US12006328B2 (en) | 2014-11-18 | 2024-06-11 | Emory University | Thieno[2,3-d]pyrimidin-4-one derivatives as NMDAR modulators and uses related thereto |
| MA41803A (fr) | 2015-03-24 | 2018-01-30 | Almirall Sa | Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques |
| AU2016291158B2 (en) | 2015-07-09 | 2020-04-30 | Janssen Pharmaceutica Nv | Substituted 4-azaindoles and their use as GluN2B receptor modulators |
| US10071988B2 (en) | 2016-02-10 | 2018-09-11 | Janssen Pharmaceutica Nv | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| JP7252908B2 (ja) | 2017-06-14 | 2023-04-05 | トレベナ・インコーポレイテッド | Ｓ１ｐ１活性を調節するための化合物およびその使用法 |
| US10766893B2 (en) | 2017-12-20 | 2020-09-08 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| WO2019193516A2 (en) | 2018-04-04 | 2019-10-10 | Janssen Pharmaceutica Nv | Substituted pyridine and pyrimidines and their use as glun2b receptor modulators |
| CN110294756A (zh) | 2019-06-04 | 2019-10-01 | 广州市原子高科同位素医药有限公司 | GluN2B亚基靶向型中枢神经系统正电子示踪剂及其制备 |
| TW202112774A (zh) | 2019-06-14 | 2021-04-01 | 比利時商健生藥品公司 | 經取代之吡唑并－吡啶醯胺及其作為ｇｌｕｎ２ｂ受體調節劑之用途 |
| BR112021025141A2 (pt) | 2019-06-14 | 2022-01-25 | Janssen Pharmaceutica Nv | Pirazolo-piridinas heteroaromáticas substituídas e seu uso como moduladores do receptor glun2b |
| AU2020293642A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators |
| CN114008052A (zh) | 2019-06-14 | 2022-02-01 | 詹森药业有限公司 | 取代的吡唑并-吡嗪以及它们作为GluN2B受体调节剂的用途 |
| MX2021015511A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Carbamatos de pirazina y sus usos como moduladores del receptor glun2b. |
| CA3143103A1 (en) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Pyridine carbamates and their use as glun2b receptor modulators |
| SG11202113174SA (en) | 2019-06-14 | 2021-12-30 | Debiopharm Int Sa | Medicament and use thereof for treating bacterial infections involving biofilm |
| PY2039449A (es) | 2019-08-01 | 2021-12-20 | Novartis Ag | Inhibidortes tricíclicos de kars dependientes de akr1c3 |
| WO2021050700A1 (en) * | 2019-09-13 | 2021-03-18 | The Broad Institute, Inc. | Cyclooxygenase-2 inhibitors and uses thereof |
| TW202426436A (zh) | 2020-06-09 | 2024-07-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和病症之化合物 |
-
2020
- 2020-06-12 CN CN202080045034.6A patent/CN114008052A/zh active Pending
- 2020-06-12 EP EP20733915.1A patent/EP3983413A1/en not_active Withdrawn
- 2020-06-12 US US16/899,847 patent/US11214563B2/en not_active Expired - Fee Related
- 2020-06-12 JP JP2021574160A patent/JP2022536773A/ja not_active Withdrawn
- 2020-06-12 CA CA3143105A patent/CA3143105A1/en active Pending
- 2020-06-12 WO PCT/EP2020/066405 patent/WO2020249802A1/en not_active Ceased
- 2020-06-12 AU AU2020292994A patent/AU2020292994A1/en not_active Abandoned
- 2020-06-12 KR KR1020227000030A patent/KR20220024403A/ko not_active Withdrawn
- 2020-06-12 MX MX2021015500A patent/MX2021015500A/es unknown
- 2020-06-12 US US17/618,068 patent/US11993587B2/en active Active
- 2020-06-12 BR BR112021024117A patent/BR112021024117A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20200392113A1 (en) | 2020-12-17 |
| US11993587B2 (en) | 2024-05-28 |
| JP2022536773A (ja) | 2022-08-18 |
| KR20220024403A (ko) | 2022-03-03 |
| AU2020292994A1 (en) | 2022-01-06 |
| CN114008052A (zh) | 2022-02-01 |
| WO2020249802A1 (en) | 2020-12-17 |
| CA3143105A1 (en) | 2020-12-17 |
| US11214563B2 (en) | 2022-01-04 |
| EP3983413A1 (en) | 2022-04-20 |
| MX2021015500A (es) | 2022-02-10 |
| US20220315590A1 (en) | 2022-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021024117A2 (pt) | Pirazolo-pirazinas substituídas e seu uso como moduladores do receptor de glun2b | |
| BR112021025141A2 (pt) | Pirazolo-piridinas heteroaromáticas substituídas e seu uso como moduladores do receptor glun2b | |
| BR112021025136A2 (pt) | Pirazolo[4,3-b]piridinas substituídas e seu uso como moduladoras do receptor de glun2b | |
| BR112021024856A2 (pt) | Amidas pirazolo-piridina substituídas e seu uso como moduladores do receptor de glun2b | |
| BR112019006691A2 (pt) | 1h-imidazo[4,5-b]piridin-2(3h)-onas substituídas e seu uso como moduladores do receptor de glun2b | |
| CO2021007993A2 (es) | Compuestos de 2‐formil‐3‐hidroxifeniloximetilo capaces de modular la hemoglobina | |
| BR112018000468A2 (pt) | 4-azaindóis substituídos e seu uso como moduladores do receptor de glun2b | |
| BR112017011972A2 (pt) | derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais | |
| DOP2018000204A (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| BR112013004766A2 (pt) | 2-amino-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3 | |
| BR112018016329A2 (pt) | 1,2,3-triazóis substituídos como moduladores de nmda seletivos para nr2b | |
| BR112021025132A2 (pt) | Carbamatos de piridina e seu uso como moduladores do receptor glun2b | |
| UY34654A (es) | Inhibidores de la beta-secretasa | |
| BR112014011333A2 (pt) | derivados de pregenen-11ss-17-21-triol-3,20-diona para o tratamento de condições oculares | |
| BR112021023562A2 (pt) | Carbamatos de pirazina e seus usos como moduladores do receptor de glun2b | |
| UY35338A (es) | Compuestos bicíclicos moduladores de la actividad de s1p1 y composiciones farmacéuticas que los contienen | |
| TN2015000032A1 (en) | Inhibitors of beta-secretase | |
| BR112016021471A8 (pt) | derivados de ácido acético azaindol e seu uso como moduladores de receptor d2 de prosrtglandina | |
| BR112022019423A2 (pt) | Moduladores de hemoglobina | |
| BR112013005056A2 (pt) | 1-oxo-di-hidroisoquinolina-3-carboxamidas substituídas como moduladores kcnq2/3 | |
| BR112016021443A8 (pt) | Derivados de ácido acético azaindol e seu uso como moduladores de receptor de prostaglandina d2 | |
| PH12021552838A1 (en) | Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators | |
| BR112017011335A2 (pt) | compostos de 4h-pirido[1,2-a]pirimidin-4-ona | |
| EA202290050A1 (ru) | ЗАМЕЩЕННЫЕ ГЕТЕРОАРОМАТИЧЕСКИЕ ПИРАЗОЛО-ПИРИДИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА GluN2B | |
| PH12021552839A1 (en) | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |